99 related articles for article (PubMed ID: 23095312)
1. Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.
Visseaux B; Charpentier C; Taieb A; Damond F; Bénard A; Larrouy L; Chêne G; Brun-Vézinet F; Matheron S; Descamps D;
AIDS; 2013 Jan; 27(2):292-5. PubMed ID: 23095312
[TBL] [Abstract][Full Text] [Related]
2. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.
Verhofstede C; Brudney D; Reynaerts J; Vaira D; Fransen K; De Bel A; Seguin-Devaux C; De Wit S; Vandekerckhove L; Geretti AM
HIV Med; 2011 Oct; 12(9):544-52. PubMed ID: 21518222
[TBL] [Abstract][Full Text] [Related]
3. High concordance of genotypic coreceptor prediction in plasma-viral RNA and proviral DNA of HIV-1 subtype C: implications for use of whole blood DNA in resource-limited settings.
Gupta S; Neogi U; Srinivasa H; Shet A
J Antimicrob Chemother; 2013 Sep; 68(9):2003-6. PubMed ID: 23633683
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
Seclén E; Del Mar González M; De Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Jul; 65(7):1493-6. PubMed ID: 20488982
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients.
Ferrer P; Montecinos L; Tello M; Tordecilla R; Rodríguez C; Ferrés M; Pérez CM; Beltrán C; Guzmán MA; Afani A
Virol J; 2013 Oct; 10():318. PubMed ID: 24165156
[TBL] [Abstract][Full Text] [Related]
6. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
Swenson LC; Dong WW; Mo T; Demarest J; Chapman D; Ellery S; Heera J; Valdez H; Poon AF; Harrigan PR
Clin Infect Dis; 2013 Jun; 56(11):1659-66. PubMed ID: 23429552
[TBL] [Abstract][Full Text] [Related]
7. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists.
Seclén E; Garrido C; González Mdel M; González-Lahoz J; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Jul; 65(7):1486-92. PubMed ID: 20427374
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
[TBL] [Abstract][Full Text] [Related]
9. Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.
Svicher V; Alteri C; Montano M; D'Arrigo R; Andreoni M; Angarano G; Antinori A; Antonelli G; Allice T; Bagnarelli P; Baldanti F; Bertoli A; Borderi M; Boeri E; Bon I; Bruzzone B; Callegaro AP; Capobianchi MR; Carosi G; Cauda R; Ceccherini-Silberstein F; Clementi M; Chirianni A; Colafigli M; D'Arminio Monforte A; De Luca A; Di Biagio A; Di Nicuolo G; Di Perri G; Di Pietro M; Di Santo F; Fabeni L; Fadda G; Galli M; Gennari W; Ghisetti V; Giacometti A; Gori C; Gori A; Gulminetti R; Leoncini F; Maffongelli G; Maggiolo F; Manca G; Gargiulo F; Martinelli C; Maserati R; Mazzotta F; Meini G; Micheli V; Monno L; Mussini C; Narciso P; Nozza S; Paolucci S; Pal G; Parisi S; Parruti G; Pignataro AR; Pollicita M; Quirino T; Re MC; Rizzardini G; Santangelo R; Scaggiante R; Sterrantino G; Turriziani O; Vatteroni ML; Vecchi L; Viscoli C; Vullo V; Zazzi M; Lazzarini A; Perno CF;
New Microbiol; 2012 Jan; 35(1):17-25. PubMed ID: 22378549
[TBL] [Abstract][Full Text] [Related]
10. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.
McGovern RA; Thielen A; Mo T; Dong W; Woods CK; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
AIDS; 2010 Oct; 24(16):2517-25. PubMed ID: 20736814
[TBL] [Abstract][Full Text] [Related]
11. Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice.
Symons J; Vandekerckhove L; Paredes R; Verhofstede C; Bellido R; Demecheleer E; van Ham PM; van Lelyveld SF; Stam AJ; van Versendaal D; Nijhuis M; Wensing AM
Clin Microbiol Infect; 2012 Jun; 18(6):606-12. PubMed ID: 21906210
[TBL] [Abstract][Full Text] [Related]
12. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
Visseaux B; Hurtado-Nedelec M; Charpentier C; Collin G; Storto A; Matheron S; Larrouy L; Damond F; Brun-Vézinet F; Descamps D;
J Infect Dis; 2012 Jan; 205(1):111-20. PubMed ID: 22140264
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy.
Bon I; Turriziani O; Musumeci G; Clò A; Montagna C; Morini S; Calza L; Gibellini D; Antonelli G; Re MC
J Med Virol; 2015 Feb; 87(2):315-22. PubMed ID: 25138591
[TBL] [Abstract][Full Text] [Related]
14. Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia.
Fabeni L; Berno G; Svicher V; Ceccherini-Silberstein F; Gori C; Bertoli A; Mussini C; Lichtner M; Zaccarelli M; Ammassari A; Pinnetti C; Cicalini S; Mastroianni CM; Andreoni M; Antinori A; Perno CF; Santoro MM
J Clin Microbiol; 2015 Sep; 53(9):2935-41. PubMed ID: 26135872
[TBL] [Abstract][Full Text] [Related]
15. High degree of concordance between flow cytometry and geno2pheno methods for HIV-1 tropism determination in proviral DNA.
Torres AJ; Brígido LF; Abrahão MH; Angelo AL; de Jesus Ferreira G; Coelho LP; Ferreira JL; Jorge CR; Netto EM; Brites C
Braz J Infect Dis; 2015; 19(2):163-9. PubMed ID: 25701547
[TBL] [Abstract][Full Text] [Related]
16. Co-receptor switch during HAART is independent of virological success.
Saracino A; Monno L; Cibelli DC; Punzi G; Brindicci G; Ladisa N; Tartaglia A; Lagioia A; Angarano G
J Med Virol; 2009 Dec; 81(12):2036-44. PubMed ID: 19856465
[TBL] [Abstract][Full Text] [Related]
17. Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure.
Rozera G; Abbate I; Giombini E; Castagna A; De Luca A; Ceccherini-Silberstein F; Cozzi Lepri A; Cassola G; Torti C; d'Arminio Monforte A; Ippolito G; Capobianchi MR;
J Antimicrob Chemother; 2014 Nov; 69(11):3085-94. PubMed ID: 25015667
[TBL] [Abstract][Full Text] [Related]
18. Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts.
Nozza S; Canducci F; Galli L; Cozzi-Lepri A; Capobianchi MR; Ceresola ER; Narciso P; Libertone R; Castelli P; Moioli M; D'Arminio Monforte A; Castagna A;
J Antimicrob Chemother; 2012 May; 67(5):1224-7. PubMed ID: 22298348
[TBL] [Abstract][Full Text] [Related]
19. Possible involvement of distinct phylogenetic clusters of HIV-1 variants in the discrepancies between coreceptor tropism predictions based on viral RNA and proviral DNA.
Kotani H; Sudo K; Hasegawa N; Fujiwara H; Hayakawa T; Iketani O; Yamaguchi M; Mochizuki M; Iwata S; Kato S
J Pharm Health Care Sci; 2016; 2():31. PubMed ID: 27833760
[TBL] [Abstract][Full Text] [Related]
20. Genotypic tropism of antiretroviral-treated patients with drug resistant HIV-1.
Parczewski M; Leszczyszyn-Pynka M; Urbanska A; Bander D; Boron-Kaczmarska A
J Med Virol; 2011 Nov; 83(11):1869-75. PubMed ID: 21915859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
